Avidity Biosciences, Inc.
RNA
$26.57
-$1.53-5.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.97M | 2.34M | 2.05M | 3.54M | 2.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.97M | 2.34M | 2.05M | 3.54M | 2.19M |
| Cost of Revenue | 95.63M | 77.20M | 63.94M | 66.83M | 52.82M |
| Gross Profit | -92.65M | -74.86M | -61.90M | -63.29M | -50.62M |
| SG&A Expenses | 28.34M | 23.27M | 20.73M | 13.90M | 16.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.96M | 100.47M | 84.67M | 80.73M | 68.94M |
| Operating Income | -120.99M | -98.13M | -82.63M | -77.19M | -66.74M |
| Income Before Tax | -102.26M | -80.40M | -70.79M | -68.86M | -60.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -102.26M | -80.40M | -70.79M | -68.86M | -60.44M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.26M | -80.40M | -70.79M | -68.86M | -60.44M |
| EBIT | -120.99M | -98.13M | -82.63M | -77.19M | -66.74M |
| EBITDA | -120.25M | -97.42M | -81.94M | -76.55M | -66.13M |
| EPS Basic | -0.80 | -0.65 | -0.66 | -0.79 | -0.79 |
| Normalized Basic EPS | -0.50 | -0.41 | -0.41 | -0.49 | -0.50 |
| EPS Diluted | -0.80 | -0.65 | -0.66 | -0.79 | -0.79 |
| Normalized Diluted EPS | -0.50 | -0.41 | -0.41 | -0.49 | -0.50 |
| Average Basic Shares Outstanding | 128.50M | 123.38M | 106.93M | 87.21M | 76.05M |
| Average Diluted Shares Outstanding | 128.50M | 123.38M | 106.93M | 87.21M | 76.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
